OCUL
Ocular Therapeutix, Inc.
$6.50
-1.66%
2026-10-23
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Key Fundamentals
Forward P/E
-6.64
EPS (TTM)
$-1.40
ROE
-73.0%
Revenue Growth (YoY)
0.1%
Profit Margin
0.0%
Debt/Equity
15.27
Price/Book
4.08
Beta
0.97
Market Cap
$2.12B
Avg Volume (10D)
2.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$11.74
60D Low
$6.00
Avg Volume
3.1M
Latest Close
$6.50
Get breakout alerts for OCUL
Sign up for Breakout Scanner to receive daily notifications when OCUL triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Ocular Therapeutix, Inc. (OCUL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors OCUL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. OCUL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.